ストックスクリーナーアプリを入手
330.41
0.12%
0.38
前日終値:
$330.03
開ける：
$328.7
24時間の取引高:
4.02M
Relative Volume:
1.52
時価総額：
$177.92B
収益：
$35.89B
当期純損益:
$7.01B
株価収益率:
25.54
EPS:
12.9352
ネットキャッシュフロー:
$11.54B
1週間 パフォーマンス:
+1.32%
1か月 パフォーマンス:
+1.12%
6か月 パフォーマンス:
+10.50%
1年 パフォーマンス:
+22.63%
1日の値動き範囲:
$326.90
$333.03
1週間の範囲:
$319.79
$333.03
52週間の値動き範囲:
$261.43
$346.38
Amgen Inc Stock (AMGN) Company Profile
AMGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
330.41 | 177.71B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-05 | アップグレード | Erste Group | Hold → Buy |
| 2025-11-24 | 再開されました | Truist | Hold |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Tradewinds LLC. Makes New $988,000 Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 93% Above Its Share Price - 富途牛牛
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - TradingView — Track All Markets
Royal Fund Management LLC Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
3,785 Shares in Amgen Inc. $AMGN Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Allstate Corp Has $5.54 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
DISCO Oncology Pact And MariTide Obesity Data Might Change The Case For Investing In Amgen (AMGN) - simplywall.st
Sequoia Financial Advisors LLC Has $45.33 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company - Yahoo Finance
Amgen’s Obesity Drug May Crush Novo Nordisk & Lilly With Just Four Shots A Year! - Smartkarma
WoodTrust Financial Corp Sells 588,232 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Cut by QRG Capital Management Inc. - MarketBeat
Pinnacle Financial Partners Inc Has $13.66 Million Stake in Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation As Shares Track Close To Analyst Targets - simplywall.st
Lobbying Update: $60,000 of AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. lobbying was just disclosed - Quiver Quantitative
Continuous Bioprocessing Market Set to Surpass Valuation of US$ 2,331.98 Million By 2035 | Astute Analytica - GlobeNewswire Inc.
Wright Investors Service Inc. Has $2.76 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen’s Stock Under the Microscope: Modest Drop, Rising Expectations and Fresh Biotech Catalysts - AD HOC NEWS
Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Amgen (AMGN) Still Attractive After A 26% One Year Share Price Gain - simplywall.st
Amgen Teases Phase 2 Results for MariTide, Its Weight-Loss Drug - Barron's
Amgen Inc. (AMGN): A Bull Case Theory - Finviz
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next - TipRanks
Amgen Expands Sleep Apnea Pipeline With Phase 3 Trial of Maridebart Cafraglutide - TipRanks
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - sharewise.com
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data - Yahoo Finance
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc. - MarketBeat
Decliners Report: Why Amgen Inc stock could rally in 20252025 Breakouts & Breakdowns & Weekly Top Performers Watchlists - moha.gov.vn
Amgen Growth Story Isn't Tapped Out Yet, Says Goldman - Benzinga
Ro partners with Amgen to study barriers to obesity care, GLP-1 access - marketscreener.com
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance - FinancialContent
Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage - marketscreener.com
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Stu - GuruFocus
Amgen Inc. $AMGN Shares Acquired by PKO Investment Management Joint Stock Co - MarketBeat
Nordea Investment Management AB Acquires 22,465 Shares of Amgen Inc. $AMGN - MarketBeat
Trickle of Data On Amgen’s MariTide Hints At Potential Of Lower Maintenance Dosing - Citeline News & Insights
Amgen to announce data on obesity drug MariTide at healthcare conference - WNWN-FM
GRIMES & Co WEALTH MANAGEMENT LLC Trims Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Citizens Financial Group Inc. RI - MarketBeat
Bogart Wealth LLC Sells 4,211 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen says MariTide helped trial patients maintain weight loss - The Mighty 790 KFGO
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
Amgen Calls 2026 a “Springboard Year” as CEO Flags Major Data, MariTide Phase 3 Push at JPM Event - MarketBeat
Amgen’s MariTide Patients Maintain Weight Loss for Two Years - Bloomberg
Amgen's Maritide: A Breakthrough in Diabetes Management - Devdiscourse
Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weight - TradingView — Track All Markets
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - Amgen
Key Executive Transition from Amgen (AMGN) to BioMarin - GuruFocus
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Lobbying Update: $37,500 of AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
Amgen Inc (AMGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
3.01%
0.93%
大文字化:
|
ボリューム (24 時間):